The Lancet Rheumatology (@thelancetrheum.bsky.social)

@thelancetrheum.bsky.social Oct 6, 2026, 1:49 PM

Read it in full here ➡️bit.ly/4rMqjLy

@thelancetrheum.bsky.social Oct 6, 2026, 1:48 PM

Read the update in full here ➡️bit.ly/4rMqjLy

@thelancetrheum.bsky.social Oct 6, 2026, 1:46 PM

NEW—CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations bit.ly/4rMqjLy
#MedSky #RheumSky #NeuroSky #HaemSky

@thelancetrheum.bsky.social Oct 2, 2026, 10:59 AM

NEW in @thelancet.com—Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation www.thelancet.com/journals/lan... #MedSky #RheumSky #PhysioSky

@thelancetrheum.bsky.social Sep 29, 2026, 3:21 PM

NEW RESEARCH—Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study bit.ly/4hujPwa

Plus, linked Comment bit.ly/4hrWLy8
#MedSky #RheumSky

Incidence of cytokine release syndrome after autologous CAR T-cell therapy by baseline biomarker. Concentrations are log scales. Dots indicate individual patients and error bars indicate 95% CIs.

@thelancetrheum.bsky.social Sep 25, 2026, 4:28 PM

NEW RESEARCH—Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study thelancet.com/journals/lan...
#MedSky #RheumSky

@thelancetrheum.bsky.social Sep 25, 2026, 10:36 AM

NEW RESEARCH—Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study www.thelancet.com/journals/lan... #MedSky #RheumSky

@thelancetrheum.bsky.social Sep 23, 2026, 8:53 AM

Our Oct 2026 issue is live!

Including research on #musculoskeletal #ultrasound and #lupus #arthritis, plus much more! thelancet.com/journals/lan...

Cover by @emma-cheng.bsky.social
#Medsky #Rheumsky

@thelancetrheum.bsky.social Sep 17, 2026, 10:16 AM

NEW RESEARCH—Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial www.thelancet.com/journals/lan... #MedSky #RheumSky

@thelancetrheum.bsky.social Sep 16, 2026, 8:50 AM

NEW COMMENT—Beyond vasomotor symptoms: reframing musculoskeletal health in the Women's Health Strategy www.thelancet.com/journals/lan...
#MedSky #RheumSky #WomensHealthSky

Proposed integration of women’s health hubs and musculoskeletal services

@thelancetrheum.bsky.social Sep 11, 2026, 9:31 AM

NEW PERSONAL VIEW—Prehabilitation in rheumatology: a missing link in psoriatic disease management www.thelancet.com/journals/lan...
#MedSky #RheumSky @stefansiebert.bsky.social

Domains of prehabilitation in psoriatic disease. Mechanistic pathways and expected outcomes are extrapolated from evidence in perioperative and chronic disease settings and adapted to psoriatic disease

@thelancetrheum.bsky.social Sep 4, 2026, 3:38 PM

NEW RESEARCH—Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study www.thelancet.com/journals/lan... #MedSky #RheumSky

@lancetimaging.bsky.social Aug 27, 2026, 11:15 AMReposted by @thelancetrheum.bsky.social

📢 We’ve published our first issue!

Read and download our inaugural issue here ➡️ www.thelancet.com/issue/S3117-...

Thank you to our authors and reviewers for their valuable contributions ✨

As a gold open access journal, our content is free to read by everyone, always. #OA

#MedSky #RadSky

@thelancetrheum.bsky.social Aug 27, 2026, 1:24 PM

NEW—ERN ReCONNET–SLICC–SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2)

Free to read with registration on lancet.com (also free): www.thelancet.com/journals/lan... #Medsky #Rheumsky